InDex Pharmaceuticals Holding AB

INDEX

SE0008966295

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-26 am EDT			5-day change	1st Jan Change
0.368 ^SEK	+5.14%		+11.85%	+43.75%

Apr. 26	InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 05	Index Pharmaceuticals Holding AB Announces Board Resignations	CI

InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 21, 2024 at 02:00 am EST

InDex Pharmaceuticals Holding AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 105.52 million compared to SEK 56.3 million a year ago. Basic loss per share from continuing operations was SEK 0.2 compared to SEK 0.11 a year ago.

Latest news about InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Index Pharmaceuticals Holding AB Announces Board Resignations	Apr. 05	CI
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease	Mar. 26	MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO	Mar. 26	CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024	Mar. 26	CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024	Mar. 26	CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development	Feb. 27	MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod	Feb. 26	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program	Nov. 21	CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee	23-10-30	CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate	23-10-20	MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea	23-10-20	CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude	23-10-11	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study	23-08-22	CI
InDex Pharmaceuticals Holding AB Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office	23-08-02	CI
InDex Pharmaceuticals Obtains New European Patent for Inflammatory Bowel Disease Drug	23-08-02	MT
InDex Pharmaceuticals Holding AB Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan	23-05-31	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Index Pharmaceuticals Holding AB Announces Positive Results from a Pharmacokinetic (PK) Study with Cobitolimod	23-03-15	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI

Chart InDex Pharmaceuticals Holding AB

Duration

Period

More charts

Company Profile

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohnâs disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.368 SEK

Average target price

0.535 SEK

Spread / Average Target

+45.38%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INDEX PHARMACEUTICALS HOLDING AB	+43.75%	17.88M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals